Viridian Therapeutics, Inc. (VRDN)
$18.30-1.93%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.6B
- Beta
- 0.96
- P/E (TTM)
- -5.16
- Short % float
- 24.35%
- Days to cover
- 8.9
- SI change
- -7.7%
- 1W
- -3.68%
- 1M
- -13.84%
- vs SPY 1W
- -4.11%
- vs SPY 1M
- -15.90%
Industry peers
FMP comparable companies · ranked by market cap
- IBRXBUYImmunityBio, Inc.$10.9BRECOVERYQ 8$10.38-3.71%
- COGTSELLCogent Biosciences, Inc.$5.3BRECOVERYQ 12$30.87-3.94%
- EWTXSELLEdgewise Therapeutics, Inc.$4.3BBEARQ 15$40.30-1.56%
- RCUSSELLArcus Biosciences, Inc.$3.1BRECOVERYQ 17$24.74-0.29%
- CLDXSELLCelldex Therapeutics, Inc.$2.2BCRISISQ 5$32.59-1.54%
- VERASELLVera Therapeutics, Inc.$2.1BCRISISQ 20$29.83-7.23%
- GLPGGalapagos N.V.$1.8B$27.98
- GPCRSELLStructure Therapeutics Inc.$1.6BCRISISQ 13$27.59-6.38%
- OCULSELLOcular Therapeutix, Inc.$1.6BCRISISQ 3$7.25+0.27%
- QURESELLuniQure N.V.$1.6BCRISISQ 17$22.80-3.32%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on VRDN?
- LOPJLB’s latest quantitative signal on Viridian Therapeutics, Inc. (VRDN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VRDN in?
- Viridian Therapeutics, Inc. (VRDN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Viridian Therapeutics, Inc. (VRDN) do?
- Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 cli…